{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:27:00Z","timestamp":1766086020475},"reference-count":38,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2000,2,15]],"date-time":"2000-02-15T00:00:00Z","timestamp":950572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2000,2,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>ChimeriVax-JE is a live, attenuated recombinant virus prepared by replacing the genes encoding two structural proteins (prM and E) of yellow fever 17D virus with the corresponding genes of an attenuated strain of Japanese encephalitis virus (JE), SA14-14-2 (T. J. Chambers et al., J. Virol. 73:3095\u20133101, 1999). Since the prM and E proteins contain antigens conferring protective humoral and cellular immunity, the immune response to vaccination is directed principally at JE. The prM-E genome sequence of the ChimeriVax-JE in diploid fetal rhesus lung cells (FRhL, a substrate acceptable for human vaccines) was identical to that of JE SA14-14-2 vaccine and differed from sequences of virulent wild-type strains (SA14 and Nakayama) at six amino acid residues in the envelope gene (E107, E138, E176, E279, E315, and E439). ChimeriVax-JE was fully attenuated for weaned mice inoculated by the intracerebral (i.c.) route, whereas commercial yellow fever 17D vaccine (YF-Vax) caused lethal encephalitis with a 50% lethal dose of 1.67 log<jats:sub>10<\/jats:sub>PFU. Groups of four rhesus monkeys were inoculated by the subcutaneous route with 2.0, 3.0, 4.0, and 5.0 log<jats:sub>10<\/jats:sub>PFU of ChimeriVax-JE. All 16 monkeys developed low viremias (mean peak viremia, 1.7 to 2.1 log<jats:sub>10<\/jats:sub>PFU\/ml; mean duration, 1.8 to 2.3 days). Neutralizing antibodies appeared between days 6 and 10; by day 30, neutralizing antibody responses were similar across dose groups. Neutralizing antibody titers to the homologous (vaccine) strain were higher than to the heterologous wild-type JE strains. All immunized monkeys and sham-immunized controls were challenged i.c. on day 54 with 5.2 log<jats:sub>10<\/jats:sub>PFU of wild-type JE. None of the immunized monkeys developed viremia or illness and had mild residual brain lesions, whereas controls developed viremia, clinical encephalitis, and severe histopathologic lesions. Immunized monkeys developed significant (\u22654-fold) increases in serum and cerebrospinal fluid neutralizing antibodies after i.c. challenge. In a standardized test for neurovirulence, ChimeriVax-JE and YF-Vax were compared in groups of 10 monkeys inoculated i.c. and analyzed histopathologically on day 30. Lesion scores in brains and spinal cord were significantly higher for monkeys inoculated with YF-Vax. ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy.<\/jats:p>","DOI":"10.1128\/jvi.74.4.1742-1751.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:37Z","timestamp":1027764397000},"page":"1742-1751","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":110,"title":["Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys"],"prefix":"10.1128","volume":"74","author":[{"given":"T. P.","family":"Monath","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->OraVax Inc., Cambridge, Massachusetts 021391;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Levenbook","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->3228 Prestwick Lane, Northbrook, Illinois 600622;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Soike","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Tulane Regional Primate Center, Covington, Louisiana 704333;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.-X.","family":"Zhang","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->OraVax Inc., Cambridge, Massachusetts 021391;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ratterree","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Tulane Regional Primate Center, Covington, Louisiana 704333;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Draper","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Sierra Biomedical Inc., Sparks, Nevada 894314; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D. T.","family":"Barrett","sequence":"additional","affiliation":[{"name":"<!--label omitted: 5-->Department of Pathology, University of Texas Medical Branch, Galveston, Texas 775555"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Nichols","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->OraVax Inc., Cambridge, Massachusetts 021391;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Weltzin","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->OraVax Inc., Cambridge, Massachusetts 021391;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Arroyo","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->OraVax Inc., Cambridge, Massachusetts 021391;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guirakhoo","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->OraVax Inc., Cambridge, Massachusetts 021391;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00571925"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00195-3"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.4.3095-3101.1999"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-71-12-2915"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1992.47.61"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1996.55.91"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121501"},{"key":"e_1_3_2_9_2","first-page":"277","article-title":"Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques","volume":"36","author":"Goverdhan M. K.","year":"1992","unstructured":"Goverdhan M. K. Kulkarni A. B. Gupta A. K. Tupe C. D. Rodrigues J. J. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques.Acta Virol. 36 1992 277 283","journal-title":"Acta Virol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.9695"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1977.26.1191"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198809083191004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890170106"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.6.4925-4930.1998"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.5527-5534.1999"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4049\/jimmunol.86.2.151","article-title":"The anamnestic antibody response to Japanese encephalitis virus in monkeys and its implications concerning naturally acquired immunity in man","volume":"86","author":"Lee H. W.","year":"1961","unstructured":"Lee H. W. Scherer W. F. The anamnestic antibody response to Japanese encephalitis virus in monkeys and its implications concerning naturally acquired immunity in man.J. Immunol. 86 1961 151 164","journal-title":"J. Immunol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-1157(87)80003-3"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1973.22.535"},{"key":"e_1_3_2_19_2","unstructured":"Monath T. P. Yellow fever Vaccines. W. B. Plotkin S. Orenstein W. 1999 815 879 Saunders and Company Philadelphia Pa"},{"key":"e_1_3_2_20_2","first-page":"399","article-title":"Mode of entry of a neurotropic arbovirus into the central nervous system: reinvestigation of an old controversy","volume":"48","author":"Monath T. P.","year":"1983","unstructured":"Monath T. P. Cropp C. B. Harrison A. K. Mode of entry of a neurotropic arbovirus into the central nervous system: reinvestigation of an old controversy.Lab. Investig. 48 1983 399 410","journal-title":"Lab. Investig."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0264-410X(98)00487-3","article-title":"Recombinant, chimaeric live, attenuated vaccine (ChimeriVax\u2122) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates","volume":"17","author":"Monath T. P.","year":"1999","unstructured":"Monath T. P. Soike K. Levenbook I. Zhang Z.-X. Arroyo J. Delagrave S. Myers G. Barrett A. D. T. Shope R. E. Chambers T. J. Guirakhoo F. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax\u2122) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine 17 1999 1869 1882","journal-title":"Vaccine"},{"key":"e_1_3_2_22_2","first-page":"327","article-title":"Infection and immunity patterns in monkeys injected with viruses of Russian spring-summer and Japanese encephalitis","volume":"62","author":"Morris J. A.","year":"1955","unstructured":"Morris J. A. Connor J. R. Smadel J. E. Infection and immunity patterns in monkeys injected with viruses of Russian spring-summer and Japanese encephalitis.Am. J. Hyg. 62 1955 327 341","journal-title":"Am. J. Hyg."},{"key":"e_1_3_2_23_2","unstructured":"National Institutes of Health Guide for the care and use of laboratory animals rev. ed. Department of Health and Human Services publication no. (NIH) 85-23. 1985 National Institutes of Health Bethesda Md"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1997.8956"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-75-6-1505"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-76-2-409"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(90)90519-W"},{"key":"e_1_3_2_28_2","first-page":"291","article-title":"The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution","volume":"375","author":"Rey F. A.","year":"1995","unstructured":"Rey F. A. Heinz F. X. Mandl C. Kunz C. Harrison S. C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.Science 375 1995 291 195","journal-title":"Science"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.60.329"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1997.56.80"},{"key":"e_1_3_2_31_2","first-page":"232","article-title":"Immunological studies with group B arthropod-borne viruses","volume":"12","author":"Rozensweig E. C.","year":"1963","unstructured":"Rozensweig E. C. Babione R. W. Wisseman C. L. Jr. Immunological studies with group B arthropod-borne viruses.Am. J. Trop. Med. Hyg. 12 1963 232 241","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Smithburn K. C. Immunology of yellow fever Yellow fever vaccination. Smithburn K. C. 1956 11 27 World Health Organization Geneva Switzerland","DOI":"10.1097\/00000441-195610000-00061"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1945.s1-25.217"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.5.1144"},{"key":"e_1_3_2_35_2","unstructured":"Tsai T. F. Chang G.-J. J. Yu Y.-X. Japanese encephalitis vaccines Vaccines. W. B. Plotkin S. Orenstein W. 1999 672 710 Saunders and Company Philadelphia Pa"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90051-K"},{"key":"e_1_3_2_37_2","first-page":"31","article-title":"Requirements for yellow fever vaccine (Requirements for Biological Substances no. 3, revised 1995)","volume":"872","author":"World Health Organization","year":"1998","unstructured":"World Health Organization Requirements for yellow fever vaccine (Requirements for Biological Substances no. 3, revised 1995).WHO Tech. Rep. Ser. 872 1998 31 68","journal-title":"WHO Tech. Rep. Ser."},{"key":"e_1_3_2_38_2","first-page":"77","article-title":"Selection of a better immunogenic and highly attenuated live vaccine virus strain of JE. I. Some biological characteristics of SA14-14-2 mutant","volume":"1","author":"Yu Y.-X.","year":"1981","unstructured":"Yu Y.-X. Wu P. F. Ao J. Liu L. H. Lim H. M. Selection of a better immunogenic and highly attenuated live vaccine virus strain of JE. I. Some biological characteristics of SA14-14-2 mutant.Chin. J. Microbiol. Immunol. 1 1981 77 84","journal-title":"Chin. J. Microbiol. Immunol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890290211"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.74.4.1742-1751.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.74.4.1742-1751.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T15:48:25Z","timestamp":1682264905000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.74.4.1742-1751.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,15]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,2,15]]}},"alternative-id":["10.1128\/JVI.74.4.1742-1751.2000"],"URL":"https:\/\/doi.org\/10.1128\/jvi.74.4.1742-1751.2000","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2,15]]},"assertion":[{"value":"1999-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-11-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}